BioSpace News Archive

First Wave BioPharma, Inc. announced that it has achieved the enrollment target in its ongoing Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

Ascendis Pharma A/S announced it will showcase its latest Endocrinology Rare Disease programs, data, and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome at ENDO 2023, the annual meeting of the Endocrine Society being held June 15-18 in Chicago.

Tiziana Life Sciences Ltd., a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD, RPh as its new Chief Operating Officer.

Compugen Ltd. announced that on June 12, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550.

Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that Ellen Snow is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, beginning on July 17, 2023.

Alkermes plc issued a letter to its shareholders in connection with the Company’s upcoming 2023 Annual General Meeting of Shareholders, which is scheduled to be held on June 29, 2023.

DEM BioPharma, Inc., an immune-oncology company developing therapies that target signals on cancer cells and myeloid phagocytes to eliminate cancer, announced the addition of Wendy Young, Ph.D., to its Scientific Advisory Board.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that management will participate in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on June 20th, 2023 at 12:30 p.m. ET.

Can-Fite BioPharma Ltd. announced that it is doing all the preparatory work for an FDA Investigational New Drug submission for the treatment of pancreatic carcinoma with Namodenoson.

PECA Labs, a medical device company reimagining vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, announced the successful first-in-human implant of the MASA Valve.